CLVSQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLVSQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Clovis Oncology's Enterprise Value is $624.5 Mil. Clovis Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-217.4 Mil. Therefore, Clovis Oncology's EV-to-EBIT for today is -2.87.
The historical rank and industry rank for Clovis Oncology's EV-to-EBIT or its related term are showing as below:
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Clovis Oncology's Enterprise Value for the quarter that ended in Sep. 2022 was $794.6 Mil. Clovis Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-217.4 Mil. Clovis Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -27.36%.
The historical data trend for Clovis Oncology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | -9.26 | -2.82 | -2.59 | -2.61 | -4.59 |
Clovis Oncology Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
EV-to-EBIT | Get a 7-Day Free Trial | -3.79 | -4.59 | -5.18 | -5.29 | -5.83 |
For the Biotechnology subindustry, Clovis Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Clovis Oncology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Clovis Oncology's EV-to-EBIT falls into.
Clovis Oncology's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 624.474 | / | -217.404 | |
= | -2.87 |
Clovis Oncology's current Enterprise Value is $624.5 Mil.
Clovis Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-217.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology (OTCPK:CLVSQ) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Clovis Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Sep. 2022 ) | = | EBIT | / | Enterprise Value (Q: Sep. 2022 ) |
= | -217.404 | / | 794.61676 | |
= | -27.36 % |
Clovis Oncology's Enterprise Value for the quarter that ended in Sep. 2022 was $794.6 Mil.
Clovis Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-217.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Clovis Oncology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas C. Harding | officer: See Remarks | 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
Gillian C Ivers-read | officer: See Remarks | C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301 |
Lindsey Rolfe | officer: See remarks | C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158 |
Daniel W Muehl | officer: See remarks | 5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862 |
Paul Edward Gross | officer: See Remarks | 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302 |
Ronit Simantov | director | 1988 CHAPEL STREET, NEW HAVEN CT 06515 |
James C Blair | director | 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204 |
Patrick J Mahaffy | director, officer: President and CEO | C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
Thorlef Spickschen | director | TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000 |
Richard A. Fair | director | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Hooks Corwin Dale | officer: See remarks | C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301 |
Paul H Klingenstein | director | 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301 |
Ginger L Graham | director | AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302 |
Brian G Atwood | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
From GuruFocus
By Business Wire Business Wire • 07-20-2022
By Business Wire Business Wire • 06-14-2022
By PRNewswire PRNewswire • 07-15-2022
By Business Wire Business Wire • 10-07-2021
By Business Wire Business Wire • 10-20-2021
By Business Wire Business Wire • 04-20-2022
By Business Wire Business Wire • 05-05-2022
By Business Wire Business Wire • 06-06-2022
By Business Wire Business Wire • 07-12-2021
By Business Wire Business Wire • 03-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.